In a study of 80 patients with acute HF with and without T2DM, empagliflozin had no effect on the NT-proBNP concentration levels but was still associated with favorable outcomes on combined endpoints of worsening heart failure, rehospitalization rates, and death at 60 days [160]. This evidence concerns the gene NPPB and type 2 diabetes mellitus.